These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15148149)

  • 1. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.
    Maruyama M; Matsui T; Tanji H; Nemoto M; Tomita N; Ootsuki M; Arai H; Sasaki H
    Arch Neurol; 2004 May; 61(5):716-20. PubMed ID: 15148149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
    Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A
    Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosing the mild cognitive impairment stage of Alzheimer's disease].
    Maruyama M; Matsui T; Tanji H; Ootsuki M; Nemoto M; Tomita N; Okamura N; Matsushita S; Higuchi S; Kodama M; Arai H; Sasaki H
    Seishin Shinkeigaku Zasshi; 2004; 106(3):269-80. PubMed ID: 15164576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
    Bjerke M; Andreasson U; Rolstad S; Nordlund A; Lind K; Zetterberg H; Edman A; Blennow K; Wallin A
    Dement Geriatr Cogn Disord; 2009; 28(4):348-56. PubMed ID: 19864909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
    Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.
    Smith EE; Egorova S; Blacker D; Killiany RJ; Muzikansky A; Dickerson BC; Tanzi RE; Albert MS; Greenberg SM; Guttmann CR
    Arch Neurol; 2008 Jan; 65(1):94-100. PubMed ID: 18195145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.
    Eckerström C; Olsson E; Klasson N; Berge J; Nordlund A; Bjerke M; Wallin A
    J Alzheimers Dis; 2015; 44(1):205-14. PubMed ID: 25201779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.
    Jicha GA; Parisi JE; Dickson DW; Johnson K; Cha R; Ivnik RJ; Tangalos EG; Boeve BF; Knopman DS; Braak H; Petersen RC
    Arch Neurol; 2006 May; 63(5):674-81. PubMed ID: 16682537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration.
    Rozzini L; Chilovi BV; Conti M; Bertoletti E; Delrio I; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1217-22. PubMed ID: 17562522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
    Grundman M; Petersen RC; Ferris SH; Thomas RG; Aisen PS; Bennett DA; Foster NL; Jack CR; Galasko DR; Doody R; Kaye J; Sano M; Mohs R; Gauthier S; Kim HT; Jin S; Schultz AN; Schafer K; Mulnard R; van Dyck CH; Mintzer J; Zamrini EY; Cahn-Weiner D; Thal LJ;
    Arch Neurol; 2004 Jan; 61(1):59-66. PubMed ID: 14732621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment.
    Rozzini L; Chilovi BV; Bertoletti E; Conti M; Del Rio I; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):550-5. PubMed ID: 16642542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer's disease.
    Defrancesco M; Marksteiner J; Deisenhammer E; Kemmler G; Djurdjevic T; Schocke M
    J Alzheimers Dis; 2013; 34(3):665-72. PubMed ID: 23254639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis.
    Gottfries J; Blennow K; Lehmann MW; Regland B; Gottfries CG
    J Geriatr Psychiatry Neurol; 2001; 14(3):109-14. PubMed ID: 11563432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.